By Colin Kellaher
Nurix Therapeutics has won a key U.S. Food and Drug Administration designation for its lead asset bexobrutideg in a rare type of non-Hodgkin's lymphoma.
Nurix on Monday said the FDA granted orphan-drug designation to bexobrutideg, also known as NX-5948, for the treatment of Waldenstrom macroglobulinemia, a slow growing type of non-Hodgkin's lymphoma characterized by the replacement of normal bone marrow cells by malignant lymphocytic cells.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. It also provides for an extended marketing exclusivity period against competition.
Nurix, a San Francisco clinical-stage biopharmaceutical company, is evaluating bexobrutideg in a Phase 1 study in patients with relapsed or refractory B cell malignancies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 07:59 ET (11:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。